|
| 1H-Isoindole-1,3(2H)-dione, 5-[5-[[3-(4-broMophenyl)-2-iMino-4-oxo-5-thiazolidinylidene]Methyl]-2-furanyl]- Basic information |
Product Name: | 1H-Isoindole-1,3(2H)-dione, 5-[5-[[3-(4-broMophenyl)-2-iMino-4-oxo-5-thiazolidinylidene]Methyl]-2-furanyl]- | Synonyms: | 1H-Isoindole-1,3(2H)-dione, 5-[5-[[3-(4-broMophenyl)-2-iMino-4-oxo-5-thiazolidinylidene]Methyl]-2-furanyl]-;BioyMifi;(E)-5-(5-((3-(4-bromophenyl)-2-imino-4-oxothiazolidin-5-ylidene)methyl)furan-2-yl)isoindoline-1,3-dione;Bioymifi 1H-Isoindole-1,3(2H)-dione, 5-[5-[[3-(4-broMophenyl)-2-iMino-4-oxo-5-thiazolidinylidene]Methyl]-2-furanyl]-;Bioymifi, 1420071-30-2;(Z)-5-(5-[(3-[4-Bromophenyl]-2-imino-4-oxothiazolidin-5-ylidene)methyl]furan-2-yl)isoindoline-1,3-dione;5-[5-[[(5Z)-3-(4-Bromophenyl)-2-imino-4-oxo-5-thiazolidinylidene]methyl]-2-furanyl]-1H-isoindole-1,3(2H)-dione;(Z)-5-(5-((3-(4-bromophenyl)-2-imino-4-oxothiazolidin-5-ylidene)methyl)furan-2-yl)isoindoline-1,3-dione (Bioymifi) | CAS: | 1420071-30-2 | MF: | C22H12BrN3O4S | MW: | 494.32 | EINECS: | | Product Categories: | Inhibitors | Mol File: | 1420071-30-2.mol | ![1H-Isoindole-1,3(2H)-dione, 5-[5-[[3-(4-broMophenyl)-2-iMino-4-oxo-5-thiazolidinylidene]Methyl]-2-furanyl]- Structure](CAS/20150408/GIF/1420071-30-2.gif) |
| 1H-Isoindole-1,3(2H)-dione, 5-[5-[[3-(4-broMophenyl)-2-iMino-4-oxo-5-thiazolidinylidene]Methyl]-2-furanyl]- Chemical Properties |
density | 1.75±0.1 g/cm3(Predicted) | storage temp. | 2-8°C | solubility | DMSO: soluble2mg/mL, clear (warmed) | form | powder | pka | 9.62±0.20(Predicted) | color | orange to dark orange red |
Hazard Codes | Xn | Risk Statements | 22 | WGK Germany | 3 |
| 1H-Isoindole-1,3(2H)-dione, 5-[5-[[3-(4-broMophenyl)-2-iMino-4-oxo-5-thiazolidinylidene]Methyl]-2-furanyl]- Usage And Synthesis |
Description | Apoptosis is induced by certain cytokines including TNF and Fas ligand in the TNF family through their death domain containing receptors. TNF-related apoptosis-inducing ligand (TRAIL or Apo2L), a member of this family, activates apoptosis in a variety of tumor cell lines by signaling through the death receptors, DR4 and DR5. Bioymifi directly activates DR5 (Kd = 1.2 μM; IC50 = 2 μM), inducing DR5 clustering, which leads to the initiation of FADD/caspase-8-dependent apoptosis in various cancer cells. | Uses | Bioymifi is thiazolidinone derivative that induces apoptosis. It is TRAIL receptor DR5 binding agent useful in human cancer cells. |
| 1H-Isoindole-1,3(2H)-dione, 5-[5-[[3-(4-broMophenyl)-2-iMino-4-oxo-5-thiazolidinylidene]Methyl]-2-furanyl]- Preparation Products And Raw materials |
|